Here’s what you want to know about FLiRT.
GREG GUTFELD: MARIANNETTE MILLER-MEEKS ‘MISSED AN OPPORTUNITY’ TO GRILL COVID-ERA OFFICIAL ABOUT RUINED LIVES
The FLiRT variants, which also come with the “parental” JN. 1 lineage of KP. 2, have three key mutations in their spike protein that can evade antibodies, according to Johns Hopkins University.
Dr. Aaron Glatt, infectious disease lead at Mount Sinai South Nassau Hospital in Oceanside, N. Y. , and a spokesman for the American Society for Infectious Diseases, said he has not noticed evidence of a buildup of illness or hospitalizations, to the best of his knowledge. He has collected clues and reports from his own patients.
U. S. experts and regulators will meet on June 5, 2024, to discuss designing a vaccine to combat new COVID variants. (Reuters/Dado Ruvic/Illustration/File photo)
“There have been significant adjustments in variants, but I think lately they haven’t been as significant, because of the immunity that a lot of other people already have” due to past illnesses and vaccines.
The CDC’s knowledge suggests that COVID-related hospitalizations have been trending downward in recent weeks, and that the number of patients in emergency departments who tested positive for COVID has remained more or less stable over the past month.
The data suggests that COVID rates are also declining year-over-year. The rate of COVID-related hospitalizations is six months lower than it was a year ago, and the amount of Paxlovid antiviral prescribed lately for COVID-19 is down about 60% from last time. year, according to analysts’ notes.
The current vaccines are still expected to have some variants opposite to the new ones, Glatt said.
CLICK HERE TO GET THE FOX NEWS APP
Since 2022, fitness regulators have asked vaccine brands to design new versions of COVID-19 vaccines to focus more on circulating variants. Last month, the European regulator said vaccine brands are targeting the JN. 1 variant. Experts and regulators will meet to discuss vaccine design on June 5 after postponing the May 16 assembly to allow more time to “gain surveillance insights and other information. “
Messenger RNA (mRNA) generation vaccine makers Pfizer with partner BioNTech and Moderna say they are waiting for the June 5 assembly before deciding on the design of their next vaccines.
Novavax, which makes a more classic protein-based vaccine that requires more time to manufacture, has generated a shot targeting JN. 1, in line with recommendations from European regulators.